The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...

2013;13(10):1207-1218. Subgroup of EGFR mutated 42 84.6 vs 37.5 (p = 0.002) 8.0 vs 6.3,HR: 0.544, p = 0.086 27.2 vs 25.6 HR: 1.043, p = n.r. HR: Hazard ratio; NSCLC: Non-small-cell lung cancer ...

Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

SELLAS Life Sciences Group has announced positive data from preclinical studies identifying the ASXL1 mutation as a ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...

the prevalence of EGFR mutations was higher in younger and female patients, whereas ALK rearrangements were found more ...

Revolution Medicines (RVMD) announced key clinical updates from its RAS(ON) inhibitor portfolio. The data to be presented during an investor ...